{"id":332850,"date":"2026-10-29T20:20:15","date_gmt":"2026-10-29T14:50:15","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/glenmark-life-sciences-q2-results-fy27-pat-197-crore\/"},"modified":"2026-10-29T20:20:15","modified_gmt":"2026-10-29T14:50:15","slug":"glenmark-life-sciences-q2-results-fy27-pat-197-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/glenmark-life-sciences-q2-results-fy27-pat-197-crore\/","title":{"rendered":"Glenmark Life Sciences Q2 Results FY27: PAT Jumps 51.31% to Rs 196.75 Cr, Revenue Rs 681.99 Cr"},"content":{"rendered":"
\n

Quick Answer<\/strong><\/p>\n

Glenmark Life Sciences Q2 Results FY27 were declared on 29 October 2026 on a standalone basis. Revenue rose 15.99% YoY to Rs 681.99 Cr from Rs 587.98 Cr, while net profit grew 51.31% to Rs 196.75 Cr from Rs 130.03 Cr. These quarterly results show positive YoY growth on revenue, Operating Profit and net profit.<\/p>\n<\/div>\n

Glenmark Life Sciences Ltd<\/a> (ALIVUS) Q2 Results FY27 announced on 29 October 2026, covering the company’s financial performance for the July to September quarter. The company reported revenue of Rs 681.99 Cr and PAT of Rs 196.75 Cr under the NSE symbol ALIVUS. Glenmark Life Sciences Q2 Results FY27 were released on this results date and are presented as standalone results.<\/p>\n

This Glenmark Life Sciences Q2 Results review is a results analysis covering the financial highlights, business drivers, outlook and risks. Univest sets out the declared numbers so the Financial Highlights table below reads alongside what changed in revenue, Operating Profit and net profit. The sections that follow keep to the figures declared on the results date.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n